[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 230", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 188, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 75000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1075600, "exercisedValue": 457971, "unexercisedValue": 20455824}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 671200, "exercisedValue": 249766, "unexercisedValue": 5641756}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 614498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 640345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723600, "exercisedValue": 0, "unexercisedValue": 4995031}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 33.45, "open": 34.65, "dayLow": 33.61, "dayHigh": 34.99, "regularMarketPreviousClose": 33.45, "regularMarketOpen": 34.65, "regularMarketDayLow": 33.61, "regularMarketDayHigh": 34.99, "payoutRatio": 0.0, "beta": 2.227, "forwardPE": -11.051447, "volume": 665873, "regularMarketVolume": 665873, "averageVolume": 580095, "averageVolume10days": 706200, "averageDailyVolume10Day": 706200, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 2232128768, "fiftyTwoWeekLow": 29.07, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 47.41946, "fiftyDayAverage": 37.523, "twoHundredDayAverage": 41.4832, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1831147008, "profitMargins": 0.0, "floatShares": 42841049, "sharesOutstanding": 64944100, "sharesShort": 7575085, "sharesShortPriorMonth": 7690384, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.1166, "heldPercentInsiders": 0.02491, "heldPercentInstitutions": 1.09944, "shortRatio": 12.81, "shortPercentOfFloat": 0.1302, "impliedSharesOutstanding": 64944100, "bookValue": 12.877, "priceToBook": 2.6690998, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -223858000, "trailingEps": -2.98, "forwardEps": -3.11, "enterpriseToRevenue": 38.901, "enterpriseToEbitda": -7.303, "52WeekChange": -0.12589014, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 34.37, "targetHighPrice": 97.0, "targetLowPrice": 41.0, "targetMeanPrice": 57.94737, "targetMedianPrice": 56.0, "recommendationMean": 1.45, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 488744000, "totalCashPerShare": 7.526, "ebitda": -250736992, "totalDebt": 87761000, "quickRatio": 7.226, "currentRatio": 7.53, "totalRevenue": 47072000, "debtToEquity": 10.503, "revenuePerShare": 0.627, "returnOnAssets": -0.20652, "returnOnEquity": -0.36382, "grossProfits": -193176000, "freeCashflow": -126831376, "operatingCashflow": -194500992, "revenueGrowth": -0.846, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -10.921689, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Kymera Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1741983811, "regularMarketTime": 1741982401, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.750368, "regularMarketPrice": 34.37, "marketState": "CLOSED", "longName": "Kymera Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "postMarketChangePercent": 0.0, "postMarketPrice": 34.37, "postMarketChange": 0.0, "regularMarketChange": 0.91999817, "regularMarketDayRange": "33.61 - 34.99", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 580095, "fiftyTwoWeekLowChange": 5.299999, "fiftyTwoWeekLowChangePercent": 0.18231852, "fiftyTwoWeekRange": "29.07 - 53.27", "fiftyTwoWeekHighChange": -18.900002, "fiftyTwoWeekHighChangePercent": -0.35479635, "fiftyTwoWeekChangePercent": -12.589014, "earningsTimestamp": 1740657600, "earningsTimestampStart": 1746016200, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1740663000, "earningsCallTimestampEnd": 1740663000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.98, "epsForward": -3.11, "epsCurrentYear": -3.73528, "priceEpsCurrentYear": -9.201451, "fiftyDayAverageChange": -3.1529999, "fiftyDayAverageChangePercent": -0.08402846, "twoHundredDayAverageChange": -7.113201, "twoHundredDayAverageChangePercent": -0.17147185, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]